NY AG leads lawsuit against 23andMe over genetic data sale plan

A coalition of 28 attorneys general, led by New York's Attorney General Letitia James, has filed a lawsuit against 23andMe to prevent the company from selling customers' genetic data without explicit consent following its March 2025 bankruptcy filing. The lawsuit aims to protect the sensitive genetic information of approximately 15 million Americans, arguing that 23andMe must comply with state laws regarding the sale or transfer of such data. The attorneys general assert that genetic information is too sensitive to be sold without each customer’s express, informed consent.

Analysis

A bipartisan coalition of 28 attorneys general, led by New York's Letitia James, has filed a lawsuit against 23andMe (trading under ticker MEHCQ following its March 2025 bankruptcy filing) to prevent the sale of sensitive genetic data from approximately 15 million customers without their explicit consent. This legal action directly challenges 23andMe's plans to auction its assets, including this valuable database, as part of its bankruptcy proceedings. The attorneys general assert that such a sale of highly personal information, including biological samples and health-related traits, would violate state laws requiring express, informed consent, a stance underscored by a prior consumer alert from the New York AG urging customers to request data deletion. The lawsuit highlights significant legal and regulatory hurdles for the bankrupt company in monetizing its primary asset, reflecting a strongly negative sentiment and critical tone towards the company's proposed actions. This situation poses a considerable risk to the value realization from 23andMe's assets during its liquidation or restructuring process.

Key Decisions for Investors

• Given 23andMe's (MEHCQ) bankruptcy status declared in March 2025, equity holders face a high probability of significant or total loss on their investment, and extreme caution is warranted.
• The lawsuit by 28 attorneys general significantly jeopardizes the potential value recoverable from the auction of 23andMe's assets, particularly its extensive customer genetic database, which may be a core component of any remaining company value.
• Investors should closely monitor the progression and outcome of this legal challenge, as it will be a critical determinant in assessing the viability and potential proceeds from the company's asset sales and could set a precedent for data privacy and monetization in the genomics sector.